{{Short description|Combination medication}} {{Use dmy dates|date=November 2021}} {{Infobox drug | type = combo | image = | width = | alt = | caption =
<!-- Combo data --> | component1 = Hydrochlorothiazide | class1 = Thiazide diuretic | component2 = Triamterene | class2 = Potassium-sparing diuretic
<!-- Clinical data --> | tradename = Dyazide, Maxzide, others | Drugs.com = {{drugs.com|ppa|hydrochlorothiazide-and-triamterene}} | MedlinePlus = | DailyMedID = Hydrochlorothiazide and triamterene | pregnancy_AU = C | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | ATC_prefix = C03 | ATC_suffix = EA01 | ATC_supplemental =
<!-- Legal status --> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_AU_comment = | legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F --> | legal_BR_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA_comment = | legal_DE = <!-- Anlage I, II, III or Unscheduled --> | legal_DE_comment = | legal_NZ = <!-- Class A, B, C --> | legal_NZ_comment = | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = <ref name="Dyazide FDA label" /><ref name="Maxzide FDA label" /> | legal_EU = | legal_EU_comment = | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> | legal_UN_comment = | legal_status = <!-- For countries not listed above -->
<!-- Identifiers --> | CAS_number = 14124-50-6 | PubChem = | IUPHAR_ligand = | DrugBank = | ChemSpiderID = | KEGG = D10269 | ChEBI = | ChEMBL = | NIAID_ChemDB = | PDB_ligand = | synonyms = co-triamterzide }}
<!-- Definition and medical uses --> '''Hydrochlorothiazide/triamterene''', also known as '''co-triamterzide''', is a fixed-dose combination medication of hydrochlorothiazide and triamterene.<ref name="Dyazide FDA label" /><ref name="Maxzide FDA label" /><ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=76|edition=76}}</ref> It is used to treat high blood pressure and edema (swelling).<ref name="Dyazide FDA label" /><ref name="Maxzide FDA label" /><ref name=BNF76/> Specifically it is used in those who develop low blood potassium (hypokalemia) when on only hydrochlorothiazide.<ref name="Dyazide FDA label"/><ref name="Maxzide FDA label" /> It is taken by mouth.<ref name="Dyazide FDA label" /><ref name="Maxzide FDA label" /><ref name=BNF76/>
<!-- Side effects and mechanisms --> Side effects may include nausea, trouble sleeping, dizziness, feeling light headed with standing, kidney problems, allergies, and muscle cramps.<ref name="Dyazide FDA label"/><ref name="Maxzide FDA label" /> Other serious side effects may include high blood potassium.<ref name="Dyazide FDA label"/><ref name="Maxzide FDA label" /> Use in pregnancy and breastfeeding is not generally recommended.<ref name="Dyazide FDA label"/><ref name="Maxzide FDA label" /> Use in those with significant kidney problems is not recommended.<ref name="Dyazide FDA label"/><ref name="Maxzide FDA label" /> It decreases blood pressure mainly by hydrochlorothiazide while triamterene decreases the amount of potassium lost.<ref name="Dyazide FDA label">{{cite web | title=Dyazide- hydrochlorothiazide and triamterene capsule | website=DailyMed | date=31 October 2017 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6eba4b6-9cd0-4c86-46a8-05a202641c89 | access-date=20 August 2020}}</ref><ref name="Maxzide FDA label">{{cite web | title=Maxzide-25- maxzide tablet Maxzide tablet | website=DailyMed | date=20 July 2018 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e92eda49-861e-4c79-b446-ec1213151d92 | access-date=20 August 2020}}</ref>
<!-- History and culture --> The combination was approved for medical use in the United States in 1965.<ref>{{cite web | title=Dyazide: FDA-Approved Drugs | website=U.S. Food and Drug Administration (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016042 | archive-url=https://web.archive.org/web/20170217083803/http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016042 | url-status=dead | archive-date=17 February 2017 | access-date=20 August 2020}}</ref> In 2023, it was the 115th most commonly prescribed medication in the United States, with more than 5{{nbsp}}million prescriptions.<ref name="Top300Drugs">{{cite web | title=Top 300 of 2023 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=12 August 2025 | archive-date=12 August 2025 | archive-url=https://web.archive.org/web/20250812130026/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Hydrochlorothiazide; Triamterene Drug Usage Statistics, United States, 2014 - 2023 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/HydrochlorothiazideTriamterene | access-date = 18 August 2025 }}</ref>
==References== {{Reflist}}
{{Diuretics}} {{GlaxoSmithKline}} {{Portal bar | Medicine}}
Category:Combination antihypertensive drugs Category:Diuretics Category:Drugs developed by GSK plc Category:Potassium-sparing diuretics Category:Thiazides Category:World Anti-Doping Agency prohibited substances Category:Wikipedia medicine articles ready to translate